Please assess the completion status of the following clinical trial:

Trial Title: Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Aged between 18 and 75 years, extremes included, male or female~* 2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia, according to the official guideline Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)~* 3. Hospitalised with a new onset respiratory illness (≤7 days since illness onset)~* 4. No family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose~* 5. Must agree not to enroll in another study of an investigational agent prior to completion of Day 30 of study~* 6. Informed Consent Form (ICF) signed voluntarily~Exclusion Criteria:~* 1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress, RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa)~* 2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory failure and mechanical ventilation required, or shock, or combined with other organ failure required ICU monitoring treatment~* 3. Severe liver disease (e.g. Child Pugh score ≥ C, AST \> 5 times upper limit)~* 4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets~* 5. Patients with definite contraindications in the label of ritonavir~* 6. Positive serum pregnancy test result for women with childbearing potential at screening~* 7. Using HIV protease inhibitor drugs~* 8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be transferred to another hospital during the study period, patient with multiple basic diseases, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASC09/ritonavir group (Type: EXPERIMENTAL): ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
- lopinavir/ritonavir group (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).